Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel

American Journal of Ophthalmology

Volumn 130, Issue 4, 2000, Pages 492-513

  Jabs, Douglas A ^a   Rosenbaum, James T ^b   Foster, C Stephen ^c   Holland, Gary N ^d   Jaffe, Glenn J ^e   Louie, James S ^f   Nussenblatt, Robert B ^g   Stiehm, E Richard ^h   Tessler, Howard ⁱ   Van Gelder, Russell N ^j   Whitcup, Scott M ^g   Yocum, David ^k  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b or 97239 4197   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JULES STEIN EYE INSTITUTE   (United States)

^e DUKE UNIVERSITY EYE CENTER   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g NATIONAL EYE INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^j WASHINGTON UNIVERSITY   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DIHYDROFOLATE REDUCTASE; DIHYDROOROTATE DEHYDROGENASE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDINE; PYRIMIDINE; TACROLIMUS;

BONE MARROW SUPPRESSION; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HUMAN; HYPERKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MUCOUS MEMBRANE PEMPHIGOID; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURINE METABOLISM; QUALITY CONTROL; REVIEW; SCLERITIS; UVEITIS;

EID: 0033807387     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(00)00659-0     Document Type: Article

References (122)

1. Rothova A., Suttorp-van Schulten M.S., Treffers W.F., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 80:1996;332-336.
2. Gross P.A., Barrett T.L., Dellinger E.P., et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis. 18:1994;421.
3. Dana M.R., Merayo-Lloves J., Schaumberg D.A., Foster C.S. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 103:1996;1846-1853.
4. Reed J.B., Morse L.S., Schwab I.R. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behçet retinitis. Am J Ophthalmol. 125:1998;409-411.
5. Polito C., La Manna A., Papale M.R., Villani G. Delayed pubertal growth spurt and normal adult height attainment in boys receiving long-term alternate-day prednisone therapy. Clin Pediatrics. 38:1999;279-285.
6. Lukert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 20:1994;630-651.
7. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 39:1996;1791-1801.
8. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 339:1998;292-299.
9. Zizic T.M., Marcoux C., Hungerford D.S., Dansereau J.V., Stevens M.B. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med. 79:1985;596-604.
10. Felson D.T., Anderson J.J. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1:1987;902-905.
11. Conn H.O., Blitzer B.L. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med. 294:1976;473-479.
12. Piper J.M., Ray W.A., Daugherty J.R., Griffin M.R. Corticosteroid use and peptic ulcer disease role of nonsteroidal anti-inflammatory drugs . Ann Intern Med. 114:1991;735-740.
13. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 37:1994;481-494.
14. Elion GB, Hitchings JH. Azathioprine. In: Handbook of experimental pharmacology. 1975;38:404-425.
15. McKendry R.J.R. Purine antagonists. Dixon J., Furst D.E. Second line agents in the treatment of rheumatic diseases. 1991;Marcell Dekker, New York.
16. Bacon P.A., Salmon M. Modes of action of second line agents. Scand J Rheumatol. 64:(suppl):1987;17-24.
17. El-Yazigi A., Wahab F.A. Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. J Clin Pharmacol. 33:1993;522-526.
18. Calin A. A placebo-controlled crossover study of azathioprine in Reiter's syndrome. Ann Rheum Dis. 95:1986;653-655.
19. Felson D.T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis results of a pooled analysis . N Engl J Med. 311:1984;1528-1533.
20. Newell F.W., Krill A.E. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK. 87:1967;499-511.
21. Andrasch R.H., Pirofsky B., Burns R.P. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 96:1978;247-251.
22. Yazici J., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 322:1990;281-285.
23. Tsokos G.C. Immunomodulatory treatments in patients with rheumatic diseases mechanism of action . Semin Arthritis Rheum. 17:1987;24-38.
24. Zimmerman T.J. Textbook of ocular pharmacology. 1997;100-101 Lippincott-Raven, Philadelphia.
25. Kremer J.M. Methotrexate and emerging therapies. Clin Exp Rheumatol. 17:1999;543-546.
26. Wallace C.A. The use of methotrexate in childhood rheumatic disease. Arthritis Rheum. 41:1998;381-391.
27. Holz F.G., Krastel H., Breitbart A., et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol. 1:1992;142-144.
28. Shah S.S., Lowder C.Y., Schmitt M.A., Wilke W.S., Kosmorsky G.S., Meisler D.M. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 99:1992;1419-1423.
29. Dev S., McCallum R.M., Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 106:1999;111-118.
30. Sandoval D.M., Alarcon G.S., Morgan S.L. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol. 34:1995;49-56.
31. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321-1325.
32. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 61:1996;1029-1037.
33. Larkin G., Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 106:1999;370-374.
34. Kilmartin D.J., Forrester J.V., Dick A.D. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 352:1998;35-36.
35. Gerber D.A., Bonham C.A., Thomson A.W. Immunosuppressive agents recent developments in molecular action and clinical application . Transplant Proc. 30:1998;1573-1579.
36. Keown P.A., Primmet D.R. Cyclosporine the principal immunosuppressant for renal transplantation . Transplant Proc. 30:1998;1712-1715.
37. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 96:1983;275-282.
38. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Randomized double-masked study of cyclosporine compared to prednisone in the treatment of endogenous uveitis. Am J Ophthalmol. 112:1991;138-146.
39. Walton R.C., Nussenblatt R.B., Whitcup S.M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 105:1998;2028-2034.
40. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., Inaba G. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's disease. Lancet. 1:1989;1093-1096.
41. Palestine A.G., Austin H.A. III, Balow J.E., et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 314:1986;1293-1298.
42. Suzuki N., Kaneko S., Ichino M., Mihara S., Wakisaka S., Sakane T. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506) experience in patients with Behçet's disease . Arthritis Rheum. 40:1997;1157-1167.
43. Fung J.J., Abu-Elmagd K., Jain A.B., et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine. Transplant Proc. 23:1991;2977-2983.
44. Fung J.J., Eliasziw M., Todo S., et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg. 183:1996;117-125.
45. Mochizuki M., Masuda K., Sakane T., et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 115:1993;763-769.
46. Ishioka M., Ohno S., Nakamura S., et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 118:1994;723-729.
47. Kilmartin D.J., Forrester J.V., Dick A.D. Tacrolimus (FK506) in failed cyclosporine A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm. 6:1998;101-109.
48. Sloper C.M., Powell R.J., Dua H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 106:1999;723-728.
49. Furst DE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, editors. Rheumatology. London: Mosby, 1998:3:9.1-3.9.10.
50. Lacki J.K., Schochat T., Sobieska M. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol. 53:1994;76-82.
51. Moore J.M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin. 20:1991;194-208.
52. Grochow L.B., Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacol. 4:1979;380-394.
53. Clements P.J. Alkylating agents. Dixon J., Furst D.E. Second line agents in the treatment of rheumatic diseases. 1991;Marcel Dekker, New York.
54. Klippel J.H., Austin H.A. III, Balow J.E., et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clinics North Am. 13:1987;47-56.
55. Fauci A.S., Wolff S.M. Wegener's granulomatosis. Studies in eighteen patients and a review of the literature. Medicine. 52:1972;535-561.
56. Wolff S.M., Fauci A.S., Horn R.G., Dale D.C. Wegener's granulomatosis. Ann Intern Med. 81:1974;513-525.
57. Fauci A.S., Haynes B.F., Katz P., Wolff S.M. Wegener's granulomatosis prospective clinical and therapeutic experience with 85 patients for 21 years . Ann Intern Med. 98:1983;76-85.
58. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener's granulomatosis an analysis of 158 patients . Ann Intern Med. 116:1992;488-498.
59. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40:1997;2187-2198.
60. Buckley C.E., Gills J.P. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med. 124:1969;29-35.
61. Ozyazgan Y., Yardakul S., Yazici H., et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome a single-masked trial . Br J Ophthalmol. 76:1992;241-243.
62. Rosenbaum J.T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 21:1994;123-125.
63. Mondino B.J., Brown S.I. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol. 96:1983;453-459.
64. Foster C.S. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 84:1986;527-663.
65. Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N. Prevention of irreversible chemotherapy-induced damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Human Reproduction. 11:1996;1620-1626.
66. Blumenfeld A., Avivi I., Ritter M., Rowe J.M. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest. 6:1999;229-239.
67. Slater C.A., Liang M.H., McCune J.W., Christman G.M., Laufer M.R. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 8:1999;3-10.
68. Chabner B.A., Allegra C.J., Curt G.A., et al. Antineoplastic agents. Hardman J.G., Limbird L.E. Goodman and Gilman's the pharmacologic basis of therapeutics. 9th edition. 1995;1233-1240 McGraw-Hill, New York.
69. Muirhead N. Management of idiopathic membranous nephropathy evidence-based recommendations . Kidney Int Suppl. 70:1997;S47-S55.
70. Mamo J.G., Azzam S.A. Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol. 84:1970;446-450.
71. Mamo J.G. Treatment of Behçet's disease with chlorambucil. A follow-up report. Arch Ophthalmol. 94:1976;580-583.
72. O'Duffy J.D., Robertson D.M., Goldstein N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med. 76:1984;75-84.
73. Abdalla M.I., Bahgat Nour E. Long-lasting remission of Behçet's disease after chlorambucil therapy. Br J Ophthalmol. 57:1973;706-711.
74. Tessler H.H., Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease. Br J Ophthalmol. 74:1990;353-357.
75. Tabbara K.F. Chlorambucil in Behçet's disease. Ophthalmology. 90:1983;906-908.
76. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment inflammatory bowel disease. Lancet. 343:1994;1249-1252.
77. Berk P.D., Goldberg J.D., Silverstein M.N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 304:1981;441-444.
78. Radis C.D., Kahl L.E., Baker G.L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. Arthritis Rheum. 38:1995;1120-1127.
79. Lane L., Tamesis R., Rodriguez A., et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology. 102:1995;1530-1535.
80. O'Dell J.R., Haire C.E., Erikson N., et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 334:1996;1287-1291.
81. Tugwell P., Pincus T., Yocum D., et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J of Med. 333:1995;137-141.
82. Weinblatt M.E.K., Bulpitt K.J., Fleischmann R.M., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate . N Engl J Med. 340:1999;253-259.
83. Pascalis L., Pia G., Aresu G., Frongia T., Barca L. Combined cyclosporine A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun. 6:1993;467-480.
84. Hooper P.I., Kaplan H.J. Triple agent immunosuppression serpiginous choroiditis. Ophthalmology. 98:1991;944-951.
85. Raja S.C., Jabs D.A., Dunn J.P., et al. Pars planitis clinical features and class II HLA associations . Ophthalmology. 106:1999;594-599.
86. Kilmartin D.J., Dick A.D., Forrester J.V. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 84:2000;259-263.
87. Mamo J.G., Baghdassarian A. Behçet's disease. A report of 28 cases. Arch Ophthalmol. 71:1964;38-41.
88. Colvard D.M., Robertson D.M., O'Duffy J.D. The ocular manifestations of Behçet's disease. Arch Ophthalmol. 95:1977;1813-1817.
89. Chajek T., Fainaru M. Behçet's disease. Report of 41 cases and a review of the literature. Medicine. 54:1975;179-196.
90. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med. 341:1999;1284-1291.
91. Mamo J.G. The rate of visual loss in Behçet's disease. Arch Ophthalmol. 84:1970;451-452.
92. Buckley C.E., Gills J.P. Cyclophosphamide therapy of Behçet's disease. J Allergy. 43:1969;273-283.
93. Ryan S.J., Maumenee A.E. Birdshot retinochoroidopathy. Am J Ophthalmol. 89:1980;31-45.
94. Gass J.D. Vitiliginous chorioretinitis. Arch Ophthalmol. 99:1981;1778-1787.
95. Priem H.A., Kjilstra A., Noens L., Baarsma G.S., De Laey J.J., Oosterhuis J.A. HLA typing in birdshot chorioretinopathy. Am J Ophthalmol. 105:1988;182-185.
96. Opremcak E.M. Birdshot retinochoroiditis. Albert D.M., Jakobiec F.A. Principles and practice of ophthalmology. Volume 1:1994;475 WB Saunders Company, Philadelphia.
97. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 101:1994;822-831.
98. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporine therapy for uveitis long-term follow-up . J Ocul Pharmacol. 1:1985;369-382.
99. LeHoang P., Girard B., Keray G., et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 20:(suppl 4):1988;128-130.
100. Nozik R.A., Dorsch W. A new chorioretinopathy associated with anterior uveitis. Am J Ophthalmol. 76:1973;758-762.
101. Callanan D., Gass J.D.M. Multifocal choroiditis and choroidal neovascularization associated with the multiple evanescent white dot and acute idiopathic blind spot enlargement syndrome. Ophthalmology. 99:1992;1678-1685.
102. Dreyer R.F., Gass J.D.M. Multifocal choroiditis and panuveitis a syndrome that mimics ocular histoplasmosis . Arch Ophthalmol. 102:1984;1776-1784.
103. Morgan C.M., Schatz H. Recurrent multifocal choroiditis. Ophthalmology. 93:1986;1138-1147.
104. Nussenblatt R.B., Whitcup S.M., Palestine A.G. White-dot syndrome. Nussenblatt R.B., Whitcup S.M., Palestine A.G. Uveitis fundamentals and clinical practice . 1996;371-384 Mosby, St. Louis.
105. Laatikainen L., Erkkila H. A follow-up study on serpiginous choroiditis. Acta Ophthalmol. 59:1981;707-718.
106. Hooper P.L., Secchi A.G., Kaplan H.J. Serpiginous choroiditis. Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular infection and immunity. 1996;579-584 Mosby, St. Louis.
107. Weiss H., Annesley W.H. Jr, Shields J.A., Tomer T., Christopherson K. The clinical course of serpiginous choroidopathy. Am J Ophthalmol. 87:1979;133-142.
108. Hardy R.A., Schatz H. Macular geographic helicoid choroidopathy. Arch Ophthalmol. 105:1987;1237-1242.
109. Secchi A.G., Tognon M.S., Maselli C. Cyclosporine-A in the treatment of serpiginous choroiditis. Int Ophthalmol. 14:1990;395-399.
110. Laatikainen L., Tarkkanen A. Failure of cyclosporine A in serpiginous choroiditis. J Ocul Therap Surg. 3:1984;280-283.
111. Watson P.G., Hayreh S.S. Scleritis and episcleritis. Br J Ophthalmol. 60:1976;163-191.
112. Foster C.S., Forstot S.L., Wilson L.A. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis effects of systemic immunosuppression . Ophthalmology. 91:1984;1253-1263.
113. Foster C.S., Sainz de la Maza M. The sclera. 1994;Springer-Verlag, New York.
114. Foster C.S., Wilson L.A., Ekins M.B. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology. 89:1982;340-353.
115. Person J.R., Rogers R.S. III. Bullous pemphigoid responding to sulfapyridine and the sulfonase. Arch Dermatol. 113:1977;610-615.
116. Nussenblatt R.B.F., Fortin E., Schiffman R., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb a phase I/II clinical trial . Proc Natl Acad Sci USA. 96:1999;7462-7466.
117. Nussenblatt R.B., Gery I., Weiner H.L., et al. Treatment of uveitis by oral administration of retinal antigens results of a phase I/II randomized masked trial . Am J Ophthalmol. 123:1997;583-592.
118. Rosenbaum J.T., George R., Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol. 127:1999;545-549.
119. Demiroglu H., Özcebe O.I., Barista D. I, ünder S., Eldem B. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease a randomized trial . Lancet. 355:2000;605-609.
120. Bermas B.L., Hill J.A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 38:1995;1722-1732.
121. Giannini E.H., Brewer E.J., Kuzmina N., et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med. 326:1992;1043-1049.
122. Tugal-Tutkan I., Havrlikova K., Power W.J., Foster C.S. Changing patterns in uveitis of childhood. Ophthalmology. 103:1996;375-383.